Comparison
Matrixyl vs. Survodutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Cosmetic
Metabolic
CAS no.
214047-00-4
2179963-22-7
Molecular weight
802.06 g/mol
4727 g/mol
Half-life
no data
168 h
Sequence
Palmitoyl-Lys-Thr-Thr-Lys-Sermodifiziertes 29-Aminosäuren-Peptid mit FettsäureseitenketteMechanism of action
Matrixyl
KTTKS is a fragment of the procollagen I sequence and appears to be part of a feedback mechanism in fibroblasts: elevated concentrations signal intact collagen synthesis and downregulate new synthesis, while low concentrations stimulate it. In cell-culture studies, stimulation of collagen types I/III, elastin, fibronectin and glycosaminoglycans has been documented. The palmitoyl modification is intended to improve skin penetration; effect at the site of action (dermal fibroblasts) depends on permeation.
Survodutide
Survodutide is a dual agonist at the GLP-1 and glucagon receptors. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at high blood glucose and modulation of satiety. The glucagon component raises basal energy expenditure via hepatic and brown adipocyte effects. A fatty-acid side chain enables albumin binding and weekly dosing.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
5
2
of which in humans
2
2
Effects recorded
3
3
Open conflicts
0
0
Documented adverse events
1
2